Last updated: 14 June 2024 at 7:00pm EST

Dr. Noreen Roth Henig Net Worth



Dr. Noreen Roth Henig biography

Dr. Noreen Roth Henig is the Chief Medical Officer at Kezar Life Sciences Inc.

What is the salary of Dr Henig?

As the Chief Medical Officer of Kezar Life Sciences Inc, the total compensation of Dr Henig at Kezar Life Sciences Inc is $616,175. There are 4 executives at Kezar Life Sciences Inc getting paid more, with John Fowler having the highest compensation of $3,532,020.



How old is Dr Henig?

Dr Henig is 56, he's been the Chief Medical Officer of Kezar Life Sciences Inc since . There are 4 older and 9 younger executives at Kezar Life Sciences Inc. The oldest executive at Kezar Life Sciences Inc is Franklin Berger, 70, who is the Independent Director.

What's Dr Henig's mailing address?

Noreen's mailing address filed with the SEC is C/O AVIDITY BIOSCIENCES, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO, CA, 92121.

Insiders trading at Kezar Life Sciences Inc

Over the last 6 years, insiders at Kezar Life Sciences Inc have traded over $3,836,099 worth of Kezar Life Sciences Inc stock and bought 6,372,267 units worth $30,891,130 . The most active insiders traders include Venture Investments Ltd Mor..., Asset Management, Lp Chen B... y Franklin M Berger. On average, Kezar Life Sciences Inc executives and independent directors trade stock every 49 days with the average trade being worth of $91,954. The most recent stock trade was executed by Mark C. Schiller on 2 July 2024, trading 6,688 units of KZR stock currently worth $3,879.



What does Kezar Life Sciences Inc do?

kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.



What does Kezar Life Sciences Inc's logo look like?

Kezar Life Sciences Inc logo

Kezar Life Sciences Inc executives and stock owners

Kezar Life Sciences Inc executives and other stock owners filed with the SEC include: